C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/WtsiPh

Status	Under development - register interest
EMMA ID	EM:14178
International strain name	C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/WtsiPh
Alternative name	EPD0025_2_A10
Strain type	Targeted Mutant Strains
Allele/Transgene symbol	Rnf10^{tm1b(KOMP)Wtsi}
Gene/Transgene symbol	Rnf10
Disclaimer	Please note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA: We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider	Wellcome Trust Sanger Institute
Provider affiliation	Wellcome Trust Sanger Institute
Genetic information	This mouse line originates from KOMP ES clone EPD0025_2_A10. For further details on the construction of this clone see the page at the IMPC portal. The critical exon(s) were flanked by loxP sites, and subsequent cre expression excised this critical sequence resulting in a knockout reporter allele using a cell permeable HTN-Cre as described in doi:10.1007/s11248-013-9764-x. Click here for more information on KOMP final vectors.
Phenotypic information	Potential phenotyping data in the IMPC portal
References	None available

Information from EMMA

Archiving centre	Institute of Molecular Genetics, Prague, Czech Republic

Disease and phenotype information

IMPC phenotypes (allele matching)

decreased bone mineral density / IMPC
decreased circulating HDL cholesterol level / IMPC
increased monocyte cell number / IMPC
enlarged heart / IMPC
microcephaly / IMPC
abnormal tibia morphology / IMPC
syndactyly / IMPC
abnormal spleen morphology / IMPC
convulsive seizures / IMPC
decreased body length / IMPC
increased anxiety-related response / IMPC
decreased anxiety-related response / IMPC
hyperactivity / IMPC
decreased locomotor activity / IMPC
abnormal gait / IMPC
decreased exploration in new environment / IMPC
limb grasping / IMPC
increased circulating triglyceride level / IMPC
increased circulating HDL cholesterol level / IMPC
increased vertical activity / IMPC
decreased mean corpuscular volume / IMPC
decreased circulating triglyceride level / IMPC
decreased vertical activity / IMPC
increased heart weight / IMPC
decreased hemoglobin content / IMPC
decreased circulating alkaline phosphatase level / IMPC
shortened QT interval / IMPC
increased lean body mass / IMPC
abnormal auditory brainstem response / IMPC
abnormal behavior / IMPC
decreased spleen weight / IMPC
decreased lymphocyte cell number / IMPC
decreased circulating cholesterol level / IMPC
improved glucose tolerance / IMPC
decreased circulating serum albumin level / IMPC
increased circulating creatinine level / IMPC
decreased circulating glucose level / IMPC
decreased mean corpuscular hemoglobin / IMPC
decreased circulating total protein level / IMPC
increased circulating sodium level / IMPC
decreased mean corpuscular hemoglobin concentration / IMPC
absent pinna reflex / IMPC
decreased prepulse inhibition / IMPC
decreased total body fat amount / IMPC
increased grip strength / IMPC
decreased grip strength / IMPC
increased red blood cell distribution width / IMPC
increased bone mineral content / IMPC
shortened ST segment / IMPC
preweaning lethality, incomplete penetrance / IMPC
decreased total retina thickness / IMPC
increased large unstained cell number / IMPC
decreased fasting circulating glucose level / IMPC
abnormal freezing behavior / IMPC
decreased thigmotaxis / IMPC
hydropic degeneration / IMPC
vacuolation / IMPC

IMPC phenotypes (gene matching)

decreased prepulse inhibition / IMPC
decreased locomotor activity / IMPC
hyperactivity / IMPC
decreased total retina thickness / IMPC
improved glucose tolerance / IMPC
increased vertical activity / IMPC
increased bone mineral content / IMPC
decreased mean corpuscular volume / IMPC
microcephaly / IMPC
decreased mean corpuscular hemoglobin concentration / IMPC
preweaning lethality, incomplete penetrance / IMPC
increased circulating glucose level / IMPC
abnormal gait / IMPC
abnormal behavior / IMPC
limb grasping / IMPC
enlarged heart / IMPC
decreased hemoglobin content / IMPC
abnormal auditory brainstem response / IMPC
decreased thigmotaxis / IMPC
decreased mean corpuscular hemoglobin / IMPC
increased monocyte cell number / IMPC
abnormal eye morphology / IMPC
decreased body length / IMPC
anophthalmia / IMPC
decreased anxiety-related response / IMPC
increased lean body mass / IMPC
vacuolation / IMPC
decreased circulating glucose level / IMPC
decreased circulating serum albumin level / IMPC
increased circulating creatinine level / IMPC
abnormal retina blood vessel morphology / IMPC
decreased bone mineral density / IMPC
decreased circulating triglyceride level / IMPC
decreased fasting circulating glucose level / IMPC
decreased exploration in new environment / IMPC
decreased circulating HDL cholesterol level / IMPC
increased grip strength / IMPC
syndactyly / IMPC
decreased spleen weight / IMPC
increased leukocyte cell number / IMPC
decreased grip strength / IMPC
hydropic degeneration / IMPC
decreased vertical activity / IMPC
abnormal bone structure / IMPC
decreased total body fat amount / IMPC
decreased circulating alkaline phosphatase level / IMPC
decreased circulating total protein level / IMPC
abnormal tibia morphology / IMPC
increased circulating aspartate transaminase level / IMPC
decreased circulating cholesterol level / IMPC
increased heart weight / IMPC
decreased brain weight / IMPC
increased circulating HDL cholesterol level / IMPC
decreased lymphocyte cell number / IMPC
shortened QT interval / IMPC
abnormal spleen morphology / IMPC
decreased hematocrit / IMPC
increased circulating triglyceride level / IMPC
increased anxiety-related response / IMPC
absent pinna reflex / IMPC
increased circulating sodium level / IMPC
abnormal freezing behavior / IMPC
increased large unstained cell number / IMPC
increased red blood cell distribution width / IMPC
shortened ST segment / IMPC
convulsive seizures / IMPC
increased circulating alanine transaminase level / IMPC
abnormal kidney morphology / IMPC

MGI phenotypes (gene matching)

decreased circulating HDL cholesterol level / MGI
increased body weight / MGI
decreased body weight / MGI
increased circulating triglyceride level / MGI
increased circulating HDL cholesterol level / MGI
increased circulating cholesterol level / MGI
decreased circulating cholesterol level / MGI

Information on how we integrate external resources can be found here

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

C57BL/6N-Rnf10tm1b(KOMP)Wtsi/WtsiPh